Context: Insulin resistance could increase insulin requirements in type 1 diabetes (T1D). Current insulin immunoassays do not detect insulin analogs. Kinase insulin receptor (IR) activation (KIRA) bioassays specific for human IR isoforms A (IR-A) and B (IR-B) permit assessment of all circulating insulin bioactivity. We studied whether IR-A and IR-B KIRA assays are related to direct measures of insulin sensitivity or insulin doses in T1D.
not helpful in assessing insulin sensitivity. The presence of insulin antibodies and the use of insulin analogs also make measurement of biologically active insulin concentrations challenging (1) . Although most patients with T1D are treated with insulin analogs, current insulin assays specifically measure unmodified human insulin (2) (3) (4) .
The insulin receptor (IR) is present as isoforms A (IR-A) and B (IR-B) in humans (5) . The IRs differ by 12 amino acids because of the alternative splicing of exon 11 of the IR gene (6) . The IRs exhibit tissue-specific expression (6) . IR-B is found predominantly in the liver but also in muscle and adipose tissue (7, 8) . IR-A is expressed ubiquitously (7) . Many tissues express both IR isoforms (6) . Insulin signaling through the IR-A predominantly stimulates proliferation, whereas insulin signaling through the IR-B stimulates glucose uptake and other insulin-mediated metabolic effects (6) .
We have developed kinase IR activation (KIRA) bioassays specific for the human IR-A and IR-B isoforms (9) (10) (11) . These bioassays use cell lines stably transfected with the human IR-A and human IR-B and quantify ligand activity by measuring ligand-induced receptor tyrosine kinase phosphorylation of the IR (10) . Autophosphorylation of the IRs starts many if not all of the biological effects mediated by insulin (12) . We previously demonstrated that IR-A and IR-B KIRA bioassays could detect IR activation by insulin analogs over a wide concentration range (11, 13) . IR KIRA bioassays therefore permit measurement of the circulating biologically active insulin in patients T1D treated with unmodified human insulin and insulin analogs (13) . In the current study we aimed to determine whether IR-A and IR-B KIRA bioassays reflect directly measured insulin action in patients with T1D and whether they correlate with insulin requirements.
Subjects and Methods

Study population
We recruited 31 patients with T1D from the outpatient clinic of the Department of Endocrinology, Helsinki University Central Hospital, and the FinnDiane (Finnish Diabetic Nephropathy Study) register, as previously described (14) . Inclusion criteria were age 18 to 65 years, body mass index (BMI) $25.0 kg/m 2 , and T1D based on a history of ketoacidosis and C-peptide levels below the lower limit of normal (0.05 nmol/L). Exclusion criteria included evidence of any acute or chronic disease other than T1D and obesity, as judged by history and physical examination, standard laboratory tests, and an electrocardiogram; alcohol consumption .20 g/d in women or .30 g/d in men; and pregnancy or lactation. The purpose and nature of the study were explained to all subjects before their written informed consent was obtained. The study protocol was approved by the Ethics Committee of the Helsinki University Central Hospital.
Study design
Screening visit
All potentially eligible patients were invited for a screening visit after a 12-hour fast. At this visit, a history and physical examination was performed. Blood samples were taken for measurement of complete blood cell counts, serum creatinine, electrolytes, alanine aminotransferase, aspartate aminotransferase, g-glutamyltransferase, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides, glucose, hemoglobin A1c (HbA1c), insulin, and C-peptide concentrations. A urinary pregnancy test was performed in women of childbearing potential.
Metabolic study including measurement of KIRA
All patients with T1D included in the study at the screening visit were invited for a metabolic study performed after a 12-hour fast. They were instructed to administer their usual insulin (analog) dose in the evening before the day of the metabolic study and not to take their usual insulin injections in the morning at the day of the metabolic study. On the day of the metabolic study, whole-body insulin sensitivity was measured via the euglycemic hyperinsulinemic clamp technique combined with infusion of D- [3- 3 H] glucose, as described later.
Whole body insulin sensitivity and insulin action on endogenous glucose production and rate of glucose disposal Whole body insulin sensitivity was determined by the euglycemic-hyperinsulinemic clamp technique combined with infusion of D- [3- 3 H] glucose to trace insulin action on glucose production (R a ) and glucose disposal (R d ) (15) . After an overnight fast, two cannulae were placed in an antecubital vein for infusion of glucose, insulin, and D- [3- 3 H] glucose and retrogradely in a heated dorsal hand vein for arterialized venous blood sampling as described (14 H] glucose (specific activity 10 to 20 Ci/mmol; PerkinElmer, Waltham, MA) was infused in a primed continuous infusion for a total of 360 minutes, as previously described (16) . After 120 minutes (time 0), insulin (Actrapid Human; Novo Nordisk, Bagsvaerd, Denmark) was started in a primed continuous infusion and continued for 240 minutes. A prolonged low-dose insulin infusion (0.4 mU/kg/min) was chosen to maximize the possibility of detecting interindividual differences in insulin inhibition of endogenous glucose R a , which is maximally suppressed already at insulin concentrations of~300 pmol/L (17). Normoglycemia was maintained by adjusting the rate of a 20% glucose infusion based on plasma glucose measurements every 5 minutes during the insulin infusion. The M-value, which reflects whole body insulin sensitivity, was determined from the glucose infusion rate after correction for changes in the glucose pool size and expressed per kilogram of fat-free mass (FFM).
GSA was determined after deproteinization of plasma with barium hydroxide and zinc sulfate and evaporation of water (18) with a liquid scintillation counter (Wallac 1409, Zaventem, Belgium). Basal R a (mg/kg FFM per minute) was calculated by dividing the D- [3- 3 H] glucose infusion rate [disintegrations per minute (dpm)/kg FFM per minute] by the steady-state concentration of GSA (dpm/mg). During the insulin infusion, the R a was calculated with Steele's non-steadystate equation (19) . Endogenous glucose R a during euglycemic hyperinsulinemia was calculated by subtracting the whole body glucose infusion rate corrected for changes in the glucose pool size (M-value) from R a during the last hour of the clamp, when glucose concentrations were comparable between individuals. The coefficients of variation for plasma glucose concentrations during the last hour were 4 6 1%, and those of GSA were 9 6 1%. R d was calculated as described (15) . The percentage suppression of endogenous R a measures insulin sensitivity of hepatic R a and was calculated by subtracting basal R a from endogenous R a during the euglycemic hyperinsulinemia divided by basal R a . The percentage suppression of FFAs by insulin was used as a measurement of insulin sensitivity to lipolysis. It was calculated by subtracting baseline FFA concentrations from FFA during the euglycemic hyperinsulinemia divided by baseline FFA.
IR-A and IR-B KIRA bioactivity
The IR-A and IR-B KIRA bioassays have been previously described (9, 11, 20) . Both bioassays use human embryonic kidney (HEK) cells stably transfected with cDNA of the human IR-A or human IR-B gene (HEK IR-A or IR-B). KIRA bioassays are based on quantification of tyrosine residue phosphorylation of the IR. For serum experiments, after 48 hours of culture, cells were stimulated for 10 minutes at 37°C. In addition, two control serum samples were tested on every plate to ensure optimal performance. Standards and serum samples were diluted in Krebs-Ringer bicarbonate buffer adjusted to pH 7.4 by CO 2 and supplemented human serum albumin diluted to 0.5% and 0.1%, respectively. Serum samples were diluted 1:10. After stimulation, cells were lysed. Crude lysates were transferred to a sandwich assay. In the IR KIRA bioassays, wells were coated with a monoclonal antibody directed against the IR (NovozymesGropep, Adelaide, Australia) that was used as capture antibody in a concentration of 2.5 mg/mL. A biotinylated antiphosphotyrosine monoclonal antibody (BAM 1676; R&D Systems Europe Ltd, Abingdon, UK) was used in a concentration of 0.2 mg/mL together with streptavidin-labeled europium (DELFIA Eu-N1; PerkinElmer Life Sciences, Groningen, The Netherlands) in a concentration of 50 pmol/L as detection antibody. Contents were read in a time-resolved fluorometer (Victor2 multilabel counter; PerkinElmer Life Sciences). Assays were performed in 48-well plates (Corning, Corning, NY). All measurements were done in duplicate. The inter-and intra-assay CVs were ,15%.
Quantification of liver fat and body composition
On the third day, liver fat content was measured in patients with T1D via 1 H-MRS with a 1.5-T Magnetom Avanto MR imager (Siemens), as previously described (16) . This measurement has been validated against that measured histologically (21) . Volumes of abdominal subcutaneous and intra-abdominal adipose tissue were quantified by magnetic resonance imaging as previously described (16) . FFM was determined by bioelectrical impedance plethysmography (BioElectrical Impedance Analyzer System model BIA-101A; RLJ Systems, Clinton Charter Township, MI) as previously described (22) .
Other analytical procedures and calculations
Fasting plasma glucose, liver enzymes, fasting serum (fS)-LDLs and fS-HDL cholesterol, fS-triglycerides, and FFA concentrations were measured as previously described (23) . S-Insulin and C-peptide concentrations were determined by time-resolved fluoroimmunoassay with insulin and C-peptide kits (AUTOdelfia; Wallac), respectively.
Statistical analysis
All data were tested for normality with KolmogorovSmirnov and Shapiro-Wilk tests. Normally distributed data are shown as mean 6 standard error of the mean (SEM), and nonnormally distributed data are shown as geometric mean 6 SEM or median followed by 25th to 75th quartiles.
Paired t tests and the Mann-Whitney U test were used to compare normally and non-normally distributed data. Spearman correlation coefficients were calculated to determine whether type IR-A or IR-B bioactivities were related to parameters of body composition, metabolism, and insulin sensitivity. Two-tailed Ps , 0.05 were considered statistically significant. The calculations were made in SPSS 21 for Windows (SPSS Inc., Chicago, IL) and figures in GraphPad software (Prism, London, UK).
Results
Fasting IR-A and IR-B and their relationship to clinical parameters Table 1 shows baseline characteristics of the patients with T1D. Of the 31 patients, almost all used a long-acting basal insulin analog (glargine, n = 16; detemir, n = 12) and a rapid-acting insulin analog (n = 30). The mean daily basal insulin dose was 31 6 3 IU (0.37 6 0.03 IU/kg) and mean daily prandial insulin dose 28 6 3 IU (0.33 6 0.03 IU/kg). Before the insulin infusion, fasting IR-A bioactivity was 53 6 7 pmol/L, and fasting IR-B bioactivity was 81 6 11 pmol/L (P , 0.001). The fasting IR-A/IR-B bioactivity ratio was 0.68 6 0.05.
The total daily insulin dose (56 6 5 IU/d, range 15-109 IU/d) was positively related to fasting IR-A and IR-B bioactivities (Fig. 1) . Both fasting IR-A and IR-B bioactivities were also positively related to HbA1c (Fig. 1) . No significant relationships were found between fasting IR-A and IR-B bioactivities and BMI, liver fat, or the volume of intra-abdominal adipose tissue (data not shown).
Both fasting IR-A and IR-B bioactivities were inversely related to whole body insulin sensitivity (M-value) (IR-A, r = 20.57, P , 0.001 and IR-B, r = 20.61, P , 0.001).
Moreover, they were both significantly positively related to endogenous R a (IR-A: r = 0.44, P = 0.01; IR-B: r = 0.38, P = 0.03).
In vivo insulin action on glucose metabolism and lipolysis and insulin action on IR-A bioactivity and IR-B bioactivity
During the insulin infusion, the median serum immunoreactive insulin concentration was 163 (154 to 190) pmol/L, and plasma glucose was 5.1 (4.8 to 6.0) mmol/L. Insulin decreased endogenous glucose R a from 3.6 (2.6 to 4.1) to 0.3 (20.7 to 0.8) (P , 0.001) and suppressed FFA by almost 90%, from 681 (521 to 837) to 77 (29 to 154) mmol/L (P , 0.001).
The infusion of exogenous insulin increased IR-A bioactivity by 25% to 66 6 8 pmol/L (P , 0.001) and IR-B bioactivity by 30% to 105 6 13 pmol/L (P , 0.001). The ratio of IR-A/IR-B bioactivity remained unchanged compared with baseline (0.65 6 0.04).
During hyperinsulinemia IR-A and IR-B bioactivities were positively related to hepatic insulin sensitivity, that is, endogenous R a during hyperinsulinemia, absolute FFA concentrations, and the percentage suppression of FFA. IR-A and IR-B bioactivities during hyperinsulinemia were inversely related to the M-value (Table 2, Fig. 2) .
The relationships between IR bioactivities and measures of insulin sensitivity are summarized in Fig. 3 . 
Discussion
In contrast to healthy subjects, in whom insulin secretion adapts to insulin resistance, measures commonly used in nondiabetic patients, such as the product of fasting insulin times glucose (homeostatic model assessment of insulin resistance), cannot be used as measures of insulin sensitivity in patients with T1D. Furthermore, the majority of currently available insulin immunoassays do not cross-react with recombinant human insulin analogs, which precludes measurement of concentrations of exogenously administered insulin (2) . Anti-insulin antibodies may also interfere with insulin measurements (1, 3, 13 ). In the current study we investigated whether measurements of circulating IR-A and IR-B bioactivity as measured by KIRA assays reflect insulin requirements or direct measures of insulin action in patients with T1D. We found both IR-A and IR-B bioactivity to be significantly correlated with insulin requirements and direct measures of insulin action, including insulin inhibition of hepatic R a and lipolysis. We used two well-validated KIRA assays to measure circulating IR-A and IR-B bioactivity. Both assays allow measurement of total insulinlike activity in human serum over a wide concentration range from 100 to 100,000 pmol/L (9, 13). Absolute IR-B bioactivity was higher than IR-A bioactivity at baseline. The latter difference is consistent with the intrinsically greater in vitro kinase activity of IR-B than IR-A (24). However, alternative explanations exist for this difference. IR protein content is significantly higher in HEK-IR-B cells than in HEK-IR-A cells (9) . Insulin analogs may also be slightly more active toward IR-B than the IR-A. Small differences in calibration of the bioassays might also have contributed to the observed differences found between IR-A and IR-B bioactivities (11) . Circulating insulinlike growth factor (IGF)-II, and perhaps IGF-I, may theoretically have contributed to bioactivity toward IR-A. However, the affinity of insulin for the IRs is 10 to 100 times higher than of IGF-II, and only free IGF-II is able to bind to IR-A (25) . Circulating IGF-II is normally sequestered by six IGF binding proteins and bound to these proteins with an affinity equal or greater than that of IGF-I and IGF-II receptors (26) .The small free fraction of IGF-II will be bound primarily to IGF-I and IGF-II receptors (27) . Therefore the relative contribution of IGF-II to IR-A bioactivity will be very low.
We chose patients with T1D whose BMI varied over a wide range, from normal to obese (maximum 38 kg/m 2 ), to have as much variation as possible in insulin requirements. In this group, identified from a large database of patients with T1D (28), we found IR bioactivity measured by the KIRA assays to correlate positively with insulin requirements and inversely with glycemic control. All patients used insulin analogs. These data are consistent with our previous data showing that both IR-A and IR-B KIRA assays detect human insulin and insulin analogs (10, 13) . They suggest that insulin antibodies, which may arise in patients treated with both human insulin and human insulin analogs (29), do not influence biologically active insulin concentrations to an extent that would preclude such a relationship from being observed. The significant associations between IR bioactivity and glycemic control suggest that insulin doses, though high in people with insulin resistance, were not high enough to combat insulin resistance.
We found three direct measures of insulin action to be significantly related to IR bioactivity (Fig. 2) . These included whole body insulin sensitivity (M-value), hepatic insulin sensitivity (endogenous R a during hyperinsulinemia), and antilipolysis (FFA concentrations during hyperinsulinemia and the percentage suppression of FFA by insulin).
In normal subjects, use of the commonly used insulin infusion rate of 1 mU/kg/min (or 40 mU/m 2 /min) completely suppresses hepatic R a within 30 minutes and reflects interindividual differences in mainly muscle insulin sensitivity (17) . We chose a low physiologic insulin infusion rate (0.4 mU/kg/min), which allows detection of interindividual differences, especially in lipolysis and hepatic insulin sensitivity (17) . The data suggest that hepatic insulin sensitivity and lipolysis may contribute to insulin requirements in T1D. Indeed, insulin sensitivity might be predicted to be a more important determinant of insulin requirements than in type 2 diabetes, given that changes in insulin secretion do not modify insulin requirements in T1D. Previous studies have documented that in insulin-deficient patients with T1D hyperglycemia results from increased R a , whereas glucose utilization under hyperglycemic conditions is either normal or increased (30) because of the mass action effect of glucose (31) . This finding implies that insulin inhibition of excessive R a determines the success of its antihyperglycemic effect. In line with the observed relationship between antilipolysis and IR bioactivity in our study, it was recently reported in mice and rats, that insulin inhibition of hepatic acetyl coenzyme A, which reflects the antilipolytic effect of insulin in adipose tissue, is critical for insulin inhibition of hepatic R a (32) .
The exogenous insulin infusion increased IR bioactivities by 25% to 30%, which seems low compared with changes in immunoreactive insulin levels. This discrepancy probably reflects fundamental differences between the IR-KIRA assay and insulin immunoassays. Both IR-KIRA assays assess the ability of a serum sample to stimulate autophosphorylation of the IR in intact cells. Compared with insulin immunoassays, they detect other factors than insulin present in serum that may contribute to the stimulation or inhibition of the IRs (33). Relationships between circulating IR-A and IR-B bioactivities, insulin action on hepatic R a and antilipolysis, insulin requirements, and glycemic control (HbA1c). Although correlations do not prove causality, the data suggest that IR or poor glycemic control increases insulin requirements, which increase both IR-A and IR-B bioactivities. *IR-A is believed to mediate predominantly proliferative effects of insulin, whereas IR-B mediates predominantly from metabolic effects (6) .
Immunoassays use insulin antibodies, which exhibit variable amounts of cross-reactivity with insulin analogs and insulin degradation products (33) . It has been reported that antibody cross-reactivity for insulin within an immunoassay system can be concentration dependent (34) . Thus, immunoassays using antibodies to insulin may not reliably reflect the amount of biological insulin activity in serum. Furthermore, the presence of insulin antibodies in serum may interfere with the currently available insulin immunoassays (1) .
Both insulin IR-A and insulin IR-B bioactivities were almost equally correlated with the metabolic parameters studied. Thus, either IR-A or IR-B measurements might be sufficient measures of insulin action, although IR-A is thought to mediate predominantly proliferative rather than metabolic effects of insulin (6) . In line with our findings, both IR isoforms display in vitro similar insulin dose-response relationships and maximal stimulation of tyrosine kinase activity (35) . The currently commercially available insulin analogs do not display isoform selectivity (36) . However, both IR isoforms probably display slight differences in insulin affinity, internalization kinetics, and postreceptor signaling capacity and dynamics (37) .
In conclusion, in T1D both IR-A and IR-B bioactivities were significantly related to insulin requirements and direct measures of insulin action, including insulin inhibition of hepatic R a and lipolysis. Measurement of IR bioactivity by KIRA assays provides a tool to assess the amount of biologically active insulin in groups of patients with T1D treated with insulin analogs.
